TB/HIV共感染患者抗结核药物浓度与药物相关毒性的关联
本研究纳入268例TB/HIV共感染患者,按WHO指南接受标准剂量抗结核治疗,于第2、8、24周给药后1、2、4小时用HPLC测定药物浓度,评估肝毒性与周围神经病变,采用Cox回归分析关联。结果显示利福平浓度与肝毒性、异烟肼浓度与周围神经病变均无关联。
要点
- 利福平Cmax在有或无肝毒性者间无差异(P=0.322)。
- 异烟肼Cmax在有或无周围神经病变者间无差异(P=0.49)。
- TB/HIV共感染患者中抗结核药物浓度与上述毒性无关联。
核心结论
- TB/HIV共感染患者中利福平浓度与肝毒性无关联,异烟肼浓度与周围神经病变无关联。
研究设计与样本
- TB/HIV共感染患者按WHO指南接受标准剂量抗结核治疗,共纳入268例,58%为男性,中位年龄34岁。
- 于治疗第2、8、24周给药后1、2、4小时用HPLC测定抗结核药物浓度。
- 肝毒性采用Division of AIDS毒性表评估,周围神经病变采用腱反射、振动觉或症状的临床评估。
- 采用Cox回归分析毒性事件与药物浓度的关联。
主要发现
- 无肝毒性、轻度、中度和重度肝毒性者的中位Cmax分别为6.57(IQR 4.83-9.41)μg/mL、7.39(IQR 5.10-10.20)μg/mL、7.00(IQR 6.05-10.95)μg/mL和3.86(IQR 2.81-14.24)μg/mL。
- 有肝毒性与无肝毒性者利福平中位Cmax无差异(P=0.322)。
- 有周围神经病变者异烟肼中位Cmax为2.34(1.52-3.23)μg/mL,无周围神经病变者为2.21(1.45-3.11)μg/mL,无差异(P=0.49)。
临床怎么用
- 在TB/HIV共感染患者中,利福平和异烟肼的浓度监测结果不宜单独用于预测肝毒性或周围神经病变风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Toxicities due to anti-TB treatment frequently occur among TB/HIV-coinfected patients. OBJECTIVES: To determine the association between anti-TB drug concentrations and the occurrence of hepatotoxicity and peripheral neuropathy among TB/HIV-coinfected patients. METHODS: TB/HIV-coinfected patients were started on standard dose anti-TB treatment according to WHO guidelines. Anti-TB drug concentrations were measured using HPLC 1, 2 and 4 h after drug intake at 2, 8 and 24 weeks following initiation of TB treatment. Participants were assessed for hepatotoxicity using Division of AIDS toxicity tables and for peripheral neuropathy using clinical assessment of tendon reflexes, vibration sensation or symptoms. Cox regression was used to determine the association between toxicities and drug concentrations. RESULTS: Of the 268 patients enrolled, 58% were male with a median age of 34 years. Participants with no hepatotoxicity or mild, moderate and severe hepatotoxicity had a median C max of 6.57 (IQR 4.83-9.41) μg/mL, 7.39 (IQR 5.10-10.20) μg/mL, 7.00 (IQR 6.05-10.95) μg/mL and 3.86 (IQR 2.81-14.24) μg/mL, respectively. There was no difference in the median C max of rifampicin among those who had hepatotoxicity and those who did not ( P = 0.322). There was no difference in the isoniazid median C max among those who had peripheral neuropathy 2.34 (1.52-3.23) μg/mL and those who did not 2.21 (1.45-3.11) μg/mL ( P = 0.49). CONCLUSIONS: There was no association between rifampicin concentrations and hepatotoxicity or isoniazid concentrations and peripheral neuropathy among TB/HIV-coinfected patients.
引用
- Sekaggya-Wiltshire C, von Braun A, Scherrer AU, et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017. PMID: 28108678. doi:10.1093/jac/dkw534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。